Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Mechanisms of resistance to topoisomerase I-targeting drugs

Oncogene volume 22, pages 7296–7304 (2003)Cite this article

Abstract

DNA topoisomerases are a class of enzymes that alter the topology of DNA and are targets of several anticancer drugs. Camptothecins (CPTs) are a relatively new family of compounds that specifically target topoisomerase I (Top1). These compounds ‘poison’ Top1 by binding to the Top1–DNA complex in a manner that prevents the religation of DNA. Topotecan and irinotecan are two CPTs that are approved for the treatment of a variety of malignancies, including colorectal, ovarian, and small cell lung cancers, as well as myeloid malignancies. Although CPTs have proven to be effective anticancer drugs, resistance is still a critical clinical problem. The mechanisms underlying de novo and acquired clinical resistance to CPTs and the newer classes of Top1 poisons are unclear. However, based on preclinical studies, it is likely that clinical resistance to these drugs is the result of: (1) inadequate accumulation of drug in the tumor, (2) resistance-conferring alterations in Top1, or (3) alterations in the cellular response to the Top1–CPT interaction. This review will focus on the current knowledge regarding mechanisms of resistance to CPTs and other Top1-targeting drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin EH and Gupta E . (1999). Anticancer Res., 19, 2067–2071.

  • Allen JD, Brinkhuis RF, Wijnholds J and Schinkel AH . (1999). Cancer Res., 59, 4237–4241.

  • Allen JD, Jackson SC and Schinkel AH . (2002). Cancer Res., 62, 2294–2299.

  • Bailly C, Carrasco C, Hamy F, Vezin H, Prudhomme M, Saleem A and Rubin E . (1999). Biochemistry, 38, 8605–8611.

  • Bearden DT and Danziger LH . (2001). Pharmacotherapy, 21, 224S–232S.

  • Benedetti P, Fiorani P, Capuani L and Wang JC . (1993). Cancer Res., 53, 4343–4348.

  • Bharti AK, Olson MO, Kufe DW and Rubin EH . (1996). J. Biol. Chem., 271, 1993–1997.

  • Bjornsti MA, Benedetti P, Viglianti GA and Wang JC . (1989). Cancer Res., 49, 6318–6323.

  • Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T and Bates SE . (1999). Cancer Res., 59, 5938–5946.

  • Buckwalter CA, Lin AH, Tanizawa A, Pommier YG, Cheng YC and Kaufmann SH . (1996). Cancer Res., 56, 1674–1681.

  • Byrne L and Bjornsti M . (2001). Proc. Am. Assoc. Cancer Res., 42, 415.

  • Champoux JJ . (2001). Annu. Rev. Biochem., 70, 369–413.

  • Chang JY, Liu JF, Juang SH, Liu TW and Chen LT . (2002). Cancer Res., 62, 3716–3721.

  • Chen AY, Yu C, Potmesil M, Wall ME, Wani MC and Liu LF . (1991). Cancer Res., 51, 6039–6044.

  • Ciotti M, Basu N, Brangi M and Owens IS . (1999). Biochem. Biophys. Res. Commun., 260, 199–202.

  • Cliby WA, Lewis KA, Lilly KK and Kaufmann SH . (2002). J. Biol. Chem., 277, 1599–1606.

  • Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF and Jodrell DI . (2002). Biochem. Pharmacol., 63, 607–613.

  • Cusack Jr JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin Jr AS . (2001). Cancer Res., 61, 3535–3540.

  • Danks MK, Garrett KE, Marion RC and Whipple DO . (1996). Cancer Res., 56, 1664–1673.

  • Danks MK, Morton CL, Pawlik CA and Potter PM . (1998). Cancer Res., 58, 20–22.

  • D'Arpa P, Beardmore C and Liu LF . (1990). Cancer Res., 50, 6919–6924.

  • Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH and Liu LF . (2001). Cancer Res., 61, 5926–5932.

  • Desai SD, Liu LF, Vazquez-Abad D and D'Arpa P . (1997). J. Biol. Chem., 272, 24159–24164.

  • Desai SD, Zhang H, Rodriguez-Bauman A, Yang J-M, Wu X, Gounder MK, Rubin EH and Liu LF . (2003). Mol. Cell Biol., 23, 2341–2350.

  • Edwards TK, Saleem A, Shaman JA, Dennis T, Gerigk C, Oliveros E, Gartenberg MR and Rubin EH . (2000). J. Biol. Chem., 275, 36181–36188.

  • Eng WK, Faucette L and Johnson RK . (1988). Mol. Pharmacol., 34, 755–760.

  • Fan Y, Weinstein JN, Kohn KW, Shi LM and Pommier Y . (1998). J. Med. Chem., 41, 2216–2226.

  • Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH and van de Vijver MJ . (2002). Clin. Cancer Res., 8, 1068–1074.

  • Fiorani P, Thimmaiah P and Bjornsti M . (2001). Proc. Am. Assoc. Cancer Res., 42, 717.

  • Fujimori A, Harker WG, Kohlhagen G, Hoki Y and Pommier Y . (1995). Cancer Res., 55, 1339–1346.

  • Gellert M . (1981). Annu. Rev. Biochem., 50, 879–910.

  • Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M . (1989). Science, 246, 1046–1048.

  • Goldwasser F, Bae I, Valenti M, Torres K and Pommier Y . (1995). Cancer Res., 55, 2116–2121.

  • Gounder M, Rajendra R, Saleem A, Zimmerman L, Yong L, Shih W, Woitowicz M, Strair R and Rubin E . (2003). Proc. Am. Assoc. Cancer Res., 44, 805.

  • Gupta E, Luo F, Lallo A, Ramanathan S, Vyas V, Rubin E and Sinko P . (2000). Anticancer Res., 20, 1013–1016.

  • Gupta E, Toppmeyer D, Zamek R, Much J, Ibrahim N, Goodin S, Kane M, Aisner J, Li XG, Haluska P, Medina M, Cornfield A, Vyas V, Natelson E, Giovanella B, Saleem A and Rubin E . (1998). Cancer Therapeut., 1, 292–301.

  • Haluska Jr P, Saleem A, Rasheed Z, Ahmed F, Su EW, Liu LF and Rubin EH . (1999). Nucleic Acids Res., 27, 2538–2544.

  • Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y and Sawada J . (2001). Xenobiotica, 31, 687–699.

  • Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM and Holguin MH . (1995). Cancer Res., 55, 1707–1716.

  • Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK and Kingsbury WD . (1989). J. Med. Chem., 32, 715–720.

  • Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M and Bates SE . (2001). Cancer Res., 61, 6635–6639.

  • Houghton PJ, Cheshire PJ, Hallman II JD, Lutz L, Friedman HS, Danks MK and Houghton JA . (1995). Cancer Chemother. Pharmacol., 36, 393–403.

  • Hsiang YH, Hertzberg R, Hecht S and Liu LF . (1985). J. Biol. Chem., 260, 14873–14878.

  • Hsiang YH, Lihou MG and Liu LF . (1989). Cancer Res., 49, 5077–5082.

  • Humerickhouse R, Lohrbach K, Li L, Bosron WF and Dolan ME . (2000). Cancer Res., 60, 1189–1192.

  • Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M and Takebayashi Y . (2001). Jpn. J. Cancer Res., 92, 452–458.

  • Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD and Kohno S . (2001). Biochem. Biophys. Res. Commun., 280, 1216–1223.

  • Kerrigan JE and Pilch DS . (2001). Biochemistry, 40, 9792–9798.

  • Khanna R, Morton CL, Danks MK and Potter PM . (2000). Cancer Res., 60, 4725–4728.

  • Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M and Kuwano M . (1997). Cancer Res., 57, 5475–5479.

  • Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H and Nishimura S . (2001). Cancer Res., 61, 2827–2832.

  • Komatani H, Morita M, Sakaizumi N, Fukasawa K, Yoshida E, Okura A, Yoshinari T and Nishimura S . (1999). Cancer Res., 59, 2701–2708.

  • Kubota N, Kanzawa F, Nishio K, Takeda Y, Ohmori T, Fujiwara Y, Terashima Y and Saijo N . (1992). Biochem. Biophys. Res. Commun., 188, 571–577.

  • Lebel M . (2001). Cell Mol. Life Sci., 58, 857–867.

  • Lebel M and Leder P . (1998). Proc. Natl. Acad. Sci. USA, 95, 13097–13102.

  • Lebel M, Spillare EA, Harris CC and Leder P . (1999). J. Biol. Chem., 274, 37795–37799.

  • Liu LF . (1989). Annu. Rev. Biochem., 58, 351–375.

  • Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G and Schellens JH . (1998). Br. J. Cancer, 77, 1645–1652.

  • Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG and Schellens JH . (1999). Cancer Res., 59, 4559–4563.

  • Mao Y, Sun M, Desai SD and Liu LF . (2000). Proc. Natl. Acad. Sci. USA, 97, 4046–4051.

  • Megonigal MD, Fertala J and Bjornsti MA . (1997). J. Biol. Chem., 272, 12801–12808.

  • Meijer M, Karimi-Busheri F, Huang TY, Weinfeld M and Young D . (2002). J. Biol. Chem., 277, 4050–4055.

  • Mirski SE and Cole SP . (1995). Cancer Res., 55, 2129–2134.

  • Mo YY, Yu Y, Shen Z and Beck WT . (2001). J. Biol. Chem., 14, 14.

  • Muller S, Hoege C, Pyrowolakis G and Jentsch S . (2001). Nat. Rev. Mol. Cell. Biol., 2, 202–210.

  • Nieves-Neira W and Pommier Y . (1999). Int. J. Cancer, 82, 396–404.

  • Nitiss J and Wang JC . (1988). Proc. Natl. Acad. Sci. USA, 85, 7501–7505.

  • Ohashi N, Fujiwara Y, Yamaoka N, Katoh O, Satow Y and Yamakido M . (1996). Jpn. J. Cancer Res., 87, 1280–1287.

  • Pandit B, Roy M, Dutta J, Padhi BK, Bhoumik G and Bhattacharyya NP . (2001). Cancer Chemother. Pharmacol., 48, 312–318.

  • Park SY, Lam W and Cheng YC . (2002). Cancer Res., 62, 459–465.

  • Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL and Zunino F . (2001). Cancer Res., 61, 6034–6037.

  • Pichierri P, Franchitto A, Piergentili R, Colussi C and Palitti F . (2001). Carcinogenesis, 22, 1781–1787.

  • Pouliot JJ, Yao KC, Robertson CA and Nash HA . (1999). Science, 286, 552–555.

  • Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross D, Bates S, Sinko P and Rubin E . (2003). Cancer Res., 63, 3228–3233.

  • Rallabhandi P, Hashimoto K, Mo YY, Beck WT, Moitra PK and D'Arpa P . (2002). J. Biol. Chem., 277, 40020–40026.

  • Rasheed ZA, Ravee Y, Saleem A and Rubin EH . (2000). Proc. Am. Assoc. Cancer Res., 41, 210.

  • Rasheed ZA, Saleem A, Ravee R, Rasheed F, Liu L and Rubin EH . (2002a). Proc. Am. Assoc. Cancer Res., 43, 1156.

  • Rasheed ZA, Saleem A, Ravee Y, Pandolfi PP and Rubin EH . (2002b). Exp. Cell Res., 277, 152–160.

  • Redinbo MR, Stewart L, Kuhn P, Champoux JJ and Hol WG . (1998). Science, 279, 1504–1513.

  • Reid RJ, Fiorani P, Sugawara M and Bjornsti MA . (1999). Proc. Natl. Acad. Sci. USA, 96, 11440–11445.

  • Reid RJ, Kauh EA and Bjornsti MA . (1997). J. Biol. Chem., 272, 12091–12099.

  • Ross DD, Karp JE, Chen TT and Doyle LA . (2000). Blood, 96, 365–368.

  • Rothenberg ML, Eckardt JR, Kuhn JG, Burris III HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ and Von Hoff DD . (1996). J. Clin. Oncol., 14, 1128–1135.

  • Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella B and Kufe D . (1994). J. Biol. Chem., 269, 2433–2439.

  • Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A and Toppmeyer D . (1995). Clin. Cancer Res., 1, 269–276.

  • Saleem A, Edwards TK, Rasheed Z and Rubin EH . (2000). Ann. NY Acad. Sci., 922, 46–55.

  • Saleem A, Rasheed Z, Rasheed F, Rajendra R, Ravee Y, Gounder M, Li H, Lutzker S, Liu L and Rubin E . (2002). Proc. Am. Assoc. Cancer Res., 43 (Suppl), 74.

  • Samejima K, Svingen PA, Basi GS, Kottke T, Mesner Jr PW, Stewart L, Durrieu F, Poirier GG, Alnemri ES, Champoux JJ, Kaufmann SH and Earnshaw WC . (1999). J. Biol. Chem., 274, 4335–4340.

  • Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS and Pommier Y . (1999). EMBO J., 18, 1397–1406.

  • Simon JA, Szankasi P, Nguyen DK, Ludlow C, Dunstan HM, Roberts CJ, Jensen EL, Hartwell LH and Friend SH . (2000). Cancer Res., 60, 328–333.

  • Smith PJ, Makinson TA and Watson JV . (1989). Int. J. Radiat. Biol., 55, 217–231.

  • Squires S, Ryan AJ, Strutt HL and Johnson RT . (1993). Cancer Res., 53, 2012–2019.

  • Stewart L, Staker B, Hjerrild K, Burgin A and Kim H . (2001). Proc. Am. Assoc. Cancer Res., 42 (Suppl), 80–81.

  • Takahashi T, Fujiwara Y, Yamakido M, Katoh O, Watanabe H and Mackenzie PI . (1997). Jpn. J. Cancer Res., 88, 1211–1217.

  • Takatani H, Oka M, Fukuda M, Narasaki F, Nakano R, Ikeda K, Terashi K, Kinoshita A, Soda H, Kanda T, Schneider E and Kohno S . (1997). Jpn. J. Cancer Res., 88, 160–165.

  • Takenaga N, Ishii M, Kamei T and Yasumori T . (2002). Drug Metab. Dispos., 30, 494–497.

  • Tamura H, Kohchi C, Yamada R, Ikeda T, Koiwai O, Patterson E, Keene JD, Okada K, Kjeldsen E and Nishikawa K . (1991). Nucleic Acids Res., 19, 69–75.

  • Tanizawa A, Beitrand R, Kohlhagen G, Tabuchi A, Jenkins J and Pommier Y . (1993). J. Biol. Chem., 268, 25463–25468.

  • ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC and Heron JF . (1997). J. Clin. Oncol., 15, 2183–2193.

  • Tsurutani J, Nitta T, Hirashima T, Komiya T, Uejima H, Tada H, Syunichi N, Tohda A, Fukuoka M and Nakagawa K . (2002). Lung Cancer, 35, 299–304.

  • Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G and Pommier Y . (2001a). Cancer Res., 61, 504–508.

  • Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P and Pommier Y . (2001b). Cancer Res., 61, 1964–1969.

  • Valkov NI, Gump JL, Engel R and Sullivan DM . (2000). Br. J. Haematol., 108, 331–345.

  • Van Wardenburg R, Gibson A and Bjornsti M . (2002). Proc. Am. Assoc. Cancer Res., 43, 793.

  • Wall ME and Wani MC . (1995). Cancer Res., 55, 753–760.

  • Walowsky C, Fitzhugh DJ, Castano IB, Ju JY, Levin NA and Christman MF . (1999). J. Biol. Chem., 274, 7302–7308.

  • Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ and Kohn KW . (1993). Cancer Res., 53, 1853–1861.

  • Wan S, Capasso H and Walworth NC . (1999). Yeast, 15, 821–828.

  • Wang H, Wang X, Zhou XY, Chen DJ, Li GC, Iliakis G and Wang Y . (2002). Cancer Res., 62, 2483–2487.

  • Wang JC . (1985). Harvey Lect., 81, 93–110.

  • Wang JC . (1996). Annu. Rev. Biochem., 65, 635–692.

  • Wang LF, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT, Whang-Peng J and Hwang J . (1997). Cancer Res., 57, 1516–1522.

  • Wessel I, Jensen PB, Falck J, Mirski SE, Cole SP and Sehested M . (1997). Cancer Res., 57, 4451–4454.

  • Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC and Potter PM . (2001). Cancer Res., 61, 5078–5082.

  • Woo MH, Vance JR, Marcos AR, Bailly C and Bjornsti MA . (2002). J. Biol. Chem., 277, 3813–3822.

  • Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E and Chen YC . (2000). Biochem. Pharmacol., 60, 831–837.

  • Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA and Houghton PJ . (1998). Clin. Cancer Res., 4, 743–753.

  • Zhang XW and Xu B . (2000). Anticancer Drugs, 11, 747–756.

  • Zhang Y, Fujita N and Tsuruo T . (1999). Int. J. Cancer, 83, 790–797.

Download references

Acknowledgements

We thank Drs Leroy F Liu, Daniel Pilch, and Ahamed Saleem for helpful discussions in writing this review.

Author information

Authors and Affiliations

  1. Department of Molecular and Cellular Pharmacology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, 08901, NJ, USA

    Zeshaan A Rasheed & Eric H Rubin

Authors
  1. Zeshaan A Rasheed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric H Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric H Rubin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rasheed, Z., Rubin, E. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22, 7296–7304 (2003). https://doi.org/10.1038/sj.onc.1206935

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206935

Keywords

This article is cited by

Search

Advanced search

Quick links